Last update:

Gastroenterology news

New approach opens rare immune cells to genetic risk research

Much of how genetic risk leads to disease has remained hidden. In many cases, genetic variants linked to disease do not act on nearby genes along the chromosome. Instead, they influence genes located far away along the DNA ...

A new target in the gut for reducing Alzheimer's risk

A compound produced by bacteria in many people's digestive tracts increases the risk of developing Alzheimer's disease and speeds cognitive decline in dementia patients, making it a potential target for a treatment that could ...

Patients with IBD face elevated risk of psychiatric disorders

Patients with inflammatory bowel disease (IBD) face a significantly higher risk of psychiatric disorders starting two to three years before diagnosis and lasting up to a decade afterward, according to a nationwide study published ...

New global research highlights burden of unsafe food

If it isn't safe, it isn't food. That message sits at the heart of a major new global effort by the World Health Organization (WHO). University of Waterloo public health researcher Dr. Shannon Majowicz contributed research ...

Colon cancer cells may change identity to metastasize

Loss of GATA6—a transcription factor that controls which genes are turned on or off—can reprogram colorectal cancer cells into more primitive, adaptable states that can then spread to the liver and establish new tumors, according ...

Engineered probiotic heads to human trials

A probiotic bioengineered by UBC Okanagan researchers to thrive in the inflamed gut is set to enter human clinical trials in Australia this summer, capping a decade-long effort to turn a beneficial bacterium into a treatment ...

Microplastics may worsen fatty liver disease, new study suggests

Microplastics—minuscule pieces of plastic broken down from larger plastic waste—are a growing concern for human health, especially for the liver. A study from the University of Oklahoma, published in Science Advances, demonstrates ...

Beyond GLP-1s: The next chapter of obesity care

The rapid rise of GLP-1 medications such as semaglutide and tirzepatide has transformed obesity treatment. Still, experts say medications alone are not enough to address one of the nation's most pressing chronic diseases.